// App-Quantinova.ai

: A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Researchers

Presenter

  • Jacob D. Soumerai

Principal Investigators

  • Masa Lasica

  • Stephen Opat

  • Chan Y. Cheah

  • Henry Chan

  • Emma Verner

  • Eva Gonzalez Barca

  • Alessandra Tedeschi

  • James Hilger

  • Yiqian Fang

  • David Simpson

  • Constantine S. Tam

Medical Centers

  • Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

  • ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

  • Linear Clinical Research, Nedlands, Australia

  • Institut Català d'Oncologia-Hospitalet, IDIBELL, Universitat de-Barcelona, Barcelona, Spain

  • Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia

  • Medical School, University of Western Australia, Crawley, Australia

  • Monash Health, Clayton, Australia

  • University of Sydney, Sydney, Australia

  • Concord Repatriation General Hospital, Concord, Australia

  • Alfred Hospital, Melbourne, Australia

  • St Vincent's Hospital Melbourne, Fitzroy, Australia

  • Monash University, Clayton, Australia

  • North Shore Hospital, Auckland, New Zealand

Locations

  • United States

  • Australia

  • Italy

  • New Zealand

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Endocrine/metabolic Diseases (ME)

Disease

  • Non-Hodgkin's Lymphoma

  • Tumor lysis syndrome

  • Hodgkin's Lymphoma

  • B cell lymphomas

  • Non‐Hodgkin Lymphoma

  • Lymphomas

Biomarkers

  • B-cell lymphoma 2

  • RNA-binding protein FUS/TLS

Drug/Treatment

  • Venetoclax

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved